Biogen posts Q1 GAAP EPS $2.67, non-GAAP $3.40; reaffirms FY23 guidance; multiple regulatory milestones

BIOGEN INC.

2023-Q1 EPS reported $2.67 revenue$2,463,000,000

Q1 revenue $2,463M (-3% YoY); GAAP EPS $2.67 (+30%); Non-GAAP EPS $3.40 (-6%).
LEQEMBI Alzheimer's drug: FDA Accelerated Approval, traditional filing Priority Review; PDUFA July 6, 2023.
Zuranolone depression NDA accepted with Priority Review; PDUFA Aug 5, 2023.
Tofersen SOD1-ALS PDUFA date April 25, 2023; Advisory Committee backed surrogate endpoint.
Appointed Chuck Triano (IR) and Adam Keeney (Corporate Dev); cost optimization program initiated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIOGEN INC. reported first quarter ended March 31, 2023 results: revenue $2,463 million, EPS $2.67. Guidance reaffirmed.

Period: first quarter ended March 31, 2023
Revenue: $2,463 million
EPS: $2.67
Guidance: reaffirmed
Result: reported results

Exact text from the filing

three potential launches in 2023; Company reports first quarter 2023 results and reaffirms full year 2023 guidance First quarter 2023 financial results • First quarter revenue $2,463 million; GAAP diluted EPS $2.67; Non-GAAP diluted EPS $3.40 Poised for leadership in Alzheimer’s disease (AD) with LEQEMBI and BIIB080 • LEQEMBI (lecanemab-irmb) FDA Accelerated

View on SEC.gov

Browse all earnings releases →

BIOGEN INC. filing history →

Source: SEC EDGAR

accession 0000875045-23-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.